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ABSTRACT: Between 1985 and 1989. many eases of Philadelphia IPh) chromosame rlegative chronic, 
myelugenous leukemia ICMLI were reported. For this review, the fl~llowing selectia~l criteria 
were used: the arigillal articles on Ph-negative cases should provide clinical, hematologic. 
cytagenetic as well as malec, ular data. In addition, eight unpublished cases af Ph-negative CML 
are i~]cluded that were studied in our institute during the last two years. Our purpase was to 
correlate presence or absence af the Ph rearrangeme~t with the clinical features in an attempt 
to test whether the entity "Ph-negative CML" really exists and to identi~y the pathalogic harac- 
teristics, frequency af occurrence, prognosis .f'or survival, and underlying maleeular mecha- 
niszns. Data on Ph-t]egative CML patients were compared with data on Ph-pasitive CML, atypical 
CML (aCMLI. and chronic mvelomoaocvtic leukemia (CMMoL). reported in the same papers as 
the Ph negative patients. Essential fl~r campariso~l of data from the dil)'erent investigators 
appeared to be a clear descriptior~ (ff criteria they used to establish the diagnosis CML. or 
alternatively a complete presentation af data fl)r all patients reported in the articles, la mast 
cases. Ph-~]egative CML was distinguishable fr()nl CMMoL and aCML, using simple criteria, e.g.. 
dil)'erential (:()ant a,~ peripheral blood and absence of dysplasia i~1 the bone nlarraw. Cytagenetic 
analysis sh()wed l~armal kary()type in most cases (ff Ph-tlegative CML. h~terestingly, in cases 
with abnormal karyatype, chranlosame 9 band q34 was relatively frequently invalved in transla- 
cations with ather chramasames than chranlasome 22, suggesting a variant Ph tral]slacatiot~ 
nat visible by cytagenetic techniques. This assumption was confirmed by an)leeular analysis. 
demanstrating bcr abl rearraz~gement i  9 out aJ" 10 af the latter cases. Results af cytogeneti(: 
and molecular investigations in 136 cases aj" Ph-negt~tive CML reviewed in this arti(:le (:learly 
indicated that molecular techniques are valuable tools for identification af bcr-abl rearrange- 
meats, indicative flJr the Ph transla(:atian. The differellt mechanisms responsible far b(:r abl 
rearrangement in Ph-negative CML patients are discussed. The question remains whether all 
Ph-negative CML patients will have bcr-abl rearrangements, or whether alternative me(:haa isms 
will be identil]ed that are responsible t'ar this disease, 
INTRODUCTION 
Chronic  mye logenous  leukemia  (CML) is a hematopo ie t i c  mal ignancy  ar is ing from 
neoplast ic  t rans format ion  of the p lur ipotent  bone marrow stem cell. S tandard  f indings 
at presentat ion  are leukocytosis ,  increased granulopoies is ,  somet imes  increased 
thrombopo ies is ,  presence of immature  granulocyt ic  progeni tors  in per iphera l  blood, 
basoph i l ia  and/or  eos inophi l ia ,  decreased leukocyte a lka l ine phosphatase  (LAP), and 
hepatosp lenomega ly .  The course of the disease is b iphas ic .  Dur ing the chron ic  phase,  
w i th  a med ian  durat ion  of 1 -4  years, the response  to chemotherapy  is usua l ly  good; 
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Table 1 Phenotypes of 200 males in the registry of X- l inkedlymphoprol i ferat ive 
disease 
Phenotype n (%) 
Fatal infectious mononut:leosis 101 (51%} 
Hypogammaglobulinemia 61 (31%/ 
Post-EBV 19 (19/29 : 66%) 
Pre-EBV 10 (10,'29 34%) 
Malignant Lymphoma 52 (26%) 
Hyperimmunoglobulinemia M 12 (6%)' 
Marrow hypoplasia 10 (5%) 
RFLP +, EBV negative, ,q (5({,i,) I~
Lymphoid vasculitus 2 [ 1%) 
Abbreviations: EB\,', Epshfin-l]arr virus; RFI,P, restriction fragment length polymorphism. 
" Not directly associated with infc.ctious mononucleosis. 
~' Six of these patients are hypogammagh)bulilaenfit:, but asymptomatic. 
ciency, such as the early il lness or death of males due to IM or ML are obtained from 
responses of families to medical- and family-history questionnaires. Files for each of 
the affected males and family members are maintained confidentially in the registry 
by kindred number. Each person is assigned a unique identification umber. This 
information and laboratory data are stored in an IBM System/370 4381 computer 
(International Business Machines, Boca Raton, FL) which is accessed through several 
IBM and Apple (Apple Computers, Cupertineo, CA) personal computers. Data are 
stored and evaluated using the Statistical Analysis System (Cary, NC) [101. 
Diagnosis of XLP 
Each patient is assessed for the diagnostic riteria of XLP: One or more of the pheno- 
types (Table 1) has to occur in two or more maternally related males [2-4]. A morpho- 
logical evaluation is made of slides of peripheral blood smears, surgical biopsy speci- 
mens, bone marrow, and tissues obtained at autopsy.To document he involvement 
of EBV, we perform a battery of tests depending on the availabil ity of samples. 
Antibody titers of IgM, IgG, and IgA isotypes against viral capsid antigen (VCA) [11, 
12], early antigen (EA) [13], and EBNA [14] are measured. We also have measured 
anti-EBNA titers by enzyme-l inked immunosorbent assay {ELISA), using a synthetic 
EBNA peptide [15]. We stain available tissue imprints for EBNA [14] and probe for 
EBV genome using Southern blots hybridized with a cocktail of EBV DNA probes 
(cosmid clones 301 99 and 302-23, provided by Beverly Griffin) in DNA extracted 
from cryopreserved tissues obtained at autopsy or from surgical biopsy specimens 
[16]. We have also performed immunoblotting studies to search for EBV-encoded 
proteins in extracts of tissues from 15 male patients who died of IM [17]. Use of in 
situ hybridization techniques specific for EBV [18] permits us to identify EBV genome 
in archival tissues, and use of the polymerase chain reaction [19, 20] enables detection 
of low levels of EBV in blood [21]. 
hnmunoglobul in levels are quantitated in plasma by radial immunodiffusion (RID) 
(Kallsted, Austin, TX) or in serum by nephelometry (Beckman ICS, Brea, CA). Serum 
IgG subclasses are measured by RID (ICN Immunobiologicals, Lysle, IL or The Binding 
Site, Birmingham, England). Reference ranges for immunoglobulin levels were estab- 
lished froin measurements made on serum from healthy Nebraskans being evaluated 
for cholesterol levels (provided by our colleague, Bruce McManus, M.D., Ph.D.) and 
from laboratory controls. 
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Figure 1 Map shows locations of 32 families with XLP in the United States. Numbers refer 
to kindred numbers. 
After initial evaluation of the patient, we obtain blood from pertinent family 
members. We measure antibody titers to EBV to seek EBV-negative males at risk for 
XLP. Iu addition, we measure antibody responses to EBV in women at risk of being 
carriers because mothers of XLP patients often have elevated antibody titers to the 
virus [22[. We have also continued to pursue karyotyping of affected males and 
carriers in search of chromosomal abnormalities that might occur at the XLP locus 
[23]. Genetic analysis using DNA probes howing restriction fragment length polymor- 
phisms to loci in the X chromosome [including DXS42, DXS37, and DXS12, which 
have been linked to the XLP locus} is performed as described previously [24-26]. 
When RFLP analysis is not informative, males at risk are challenged intravenously 
with bacteriophage 0X174 because males with XLP do not switch from IgM to lgG 
antibody production on secondary challenge with 0X174 [27. 28]. 
RESULTS 
Two hundred forty males with XLP within 59 unrelated kindreds had been referred 
to the International XLP Registry by December 1989. Among the 222 males whose 
fate is known, 181 (82%) have died and 41 (18%) are living. Figures 1 and 2 show the 
geographical locations of the families. Noteworthy is the frequent recognition of XLP 
in the United States, Canada, the United Kingdom, Europe, and the Mideast, and the 
lack of cases referred from Central and South America, Africa, the nations of the 
Warsaw Pact, and the highly populated countries of Asia, including China, India, 
Indonesia, and Japan. 
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CML, atypical CML (aCML), and CMMoL. Not all hematologists are in agreement with 
these rather strict proposals, but they reflect on it anti describe their own discrilninat- 
ing features for establishing the diagnosis of CML. The criteria for CML followed by 
the different investigators are summarized in Table 2. 
Generally, there is consensus on the most essential features, i.e., leucocytosis, 
basophil ia, hepatosp]enomegaly, absence of absolute monocytosis, and absence of 
MDS or ANLL characteristics. As a consequence, the percentage ofcases of Ph negative 
CML has been reduced from 10%-15% [2-4] to less than 5%, mainly by elimination 
of cases fulfilling tbe presently established criteria for CMMoL, jCML, MDS, and 
ANLL. Discrimination hetween Ph-positive and Ph-negative CML is not possible using 
clinical or helnatologic characteristics only. The remaining roup of patients with Ph- 
negative CML still appears heterogeneous and comprises cases that are clinically aud 
bematologically indistinguishable from Ph-positive CML, including long survival and 
good therapeutic response. Other cases are atypical but resemble CML more than 
other well defined hematologic disorders. These are designed as aCML [30, 31 I. 
Cytogenetic Findings in Ph Negative CML 
In 127 patients, cytogenetic studies were performed at diagnosis or during the chronic 
phase of CML. In 9 other patients analysis was performed after blastic transformation. 
During chronic phase, the karyotype was found to be normal in 48 patients (Table 3); 
abnormal in 15 cases (Table 4); and Ph-negative, not specifying other chromosolnal 
abnormalities, in 64 cases (Table 5). Among the 15 abnormal karyotypes, 10 showed 
a translocation involving chromosome 9 band q34, which is the chromosomal site 
involved in the Ph translocation (Table 4A). This is highly suggestive for a variant Ph 
translocation, in which the microscopic aspect of chromosome 22 is not visibly 
altered. Molecular studies confirmed this assumption, as discussed later. The rest of 
this group of chronic-phase CML patients with cytogenetically abnormal karyotype 
showed random clonal abnormalities (Table 4B). In a few patients, other translocations 
are detected, usually associated with subtypes of ANLL such as t(8;21), described by 
Wiedemann et al. [31], in a patient with atypical CML (Table 4D). 
Three out of nine cases in blast crisis showed cytogenetic abnormalities (Table 
4C). Remarkably, trisomy 8 and i(17q) were found in the latter cases ]32]. These 
abnormalities are identical to the ones associated with blastic transformation of Ph- 
positive CML. The resemblance between Ph-negative and Ph-positive CML is also 
expressed in the clonal and multipotent stem cell origin of both Ph-positive and Ph- 
negative CML [33] and in the occurrence of lymphoid, myeloid, mixed and undifferen- 
tiated blast crisis of Ph-negative and Ph-positive CML 134, 35]. 
MoLecular Investigations in Ph-Negative CML 
The purpose of molecular investigations in Ph-negative CML is to identify the patients 
with bcr-abl rearrangeineut oil DNA, RNA, or protein level. Comparison of cytoge- 
netic, molecular, and clinical data between Ph-negative CML patients with or without 
bcr rearrangelnent and Ph-positive CML patients is important o determine the func- 
tional meaning of the Ph chronmsome itself. Therefore, the strategy followed by all 
investigators was to screen Ph-negative CML cases for: 
1. The presence of BCR breakpoint using Southern blot analysis. 
2. Localization of c-abl, bcr, and c-sis oncogenes on the chromosomes applying in 
situ hybridization techniques. 
3. Expression of bcr-abl mRNA using Northern blot, RNAse protection assay, or 
polymerase chain reaction (PCR) techniques. Both the RNAse protection assay and 
PCR technique give the opportunity to identify which BCR exou is fused to abl. In 
CML patients with t(9:22), usually BCR exon 2 (b2) or BCR exon 3 (b3) is fused to 
ab lexon 2 (a2), restl l t ingin b2a2 orb3a2 t)cr abl fusion region [36]. 
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Tab le  3 Mo lecu la r  data  on  CML pat ients  w i th  normal  karyotype  of leukemic  ce l l s  
No. of BCR P210 In situ 
cases breakpoint bcr-abl mRNA bcr-abl hybridizat ion Reference 
A. Patients with CML (n = 48) 
1 ND 
1 + 
1 
2 
1 + 
6 
1 + 
1 + 
1 +"  ND 
1 + +, (b~a_, + [ha~) 
1 
1 
1 
2 
1 
7 ': 
4 ~: 
4 
1 
1 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+,  (b:la,) 
ND 
+,  (b2a2] 
+,  (b3a2) 
+,  (b2a2) 
ND 
+ (4/4) h 
c-sis on 22 
c-abl on 9q34 
c-abl on 9q/22q 
c-s/s, 3'bcr  on 22 
ND 
ND 
{ c-abl on 9/22 bcr on 22q l l  
c-sis on 22 
e-abl,  bcr on 22q l l  
c-abl, bcr on 22q l l  
5'bcr, c-abl on lp  
3'bcr  on 9 
c-sis on 22 
5'bcr, c-abl on lp  
3'bcr, c-sis on 22 
Bartram et al. 
[1984) [621 
Bartram et al. 
[1985) I47] 
Kurzrock et al. 
(1986) [44] 
Kurzrock et al. 
(1986) [44] 
Bartram et al. 
(1986) [58] 
Bartram et al. 
(1986) [58] 
Morris et al. 
(1986) [46] and 
Fitzgerald et al. 
(1987) [59] 
Morris et al. 
(1986) [46] and 
Fitzgerald et al. 
(1987) [591 
Ganesan et al. 
(1986) [42] and 
Dreazen et al. 
(1987) [41] 
Ganesan et al. 
(1986) [42] and 
Dreazen et al. 
{1987] [41[ 
Dreazen e,t al. 
(1987) [41] 
Dreazen et al. 
(1987) [41] 
Ohyashik i  et al. 
[1988) [61] 
Weinstein et al. 
(1988) [63] 
Eisenberg et al. 
(1988) [64] 
Wiedemann et al. 
(1988) [31] 
Wiedemann et al. 
(1988) [311 
Bartram et al. 
(1988) i321 
LoCoco et al. 
(1989) [65] 
Van der Plas et al. 
(1989) [45] 
Van der Plas et al. 
(1989) [45] 
Van der Plas et al. 
(this report) 
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Tab le  3 (Continued) 
No. of BCR P210 In situ 
cases breakpoint bcr-abl mRNA bcr-abl hybridization Reference 
7 - - '{5/5J h
B. Patients with CML BC (n = 6) 
1 
4 
1 + 
C. Patients with atypical CML (n - 16) 
1 +~' 
1 + 
2 + + (b2a2) 
2 
4 
6 
- ,  (2/4) b 
Van der Plas et al. 
(this report) 
Bartram et al. 
(1986) [58] 
Maxwell et al. 
(1987) [341 
Ohyashiki et al. 
(19881 [611 
Ganesan et al. 
(1986} 142] 
Ganesan et al. 
(1986) [42] 
Dreazen et al. 
(1987) [41] 
Ohyashiki et al. 
(1988) 1611 
Wiedemann et al. 
(1988) [311 
Cogswell et al. 
(1989) [55] 
Abbreviution: ND. not done. 
"Extra bands in one restriction enzyme digest. 
~'Number ofcases observed/number of cases investigated. 
CCML diagnosis could not be verified. 
4. Detection of 210 kD bcr-abl protein (P210), e.g., by means of autophosphorylation 
assays. 
The results of these molecular investigations are presented in detail in Tables 3-6 
together with the corresponding cytogenetic data. (An overview of these data for CML 
patients is provided in Table 7.) 
In summary, we can make the following points: 
1) Fifty-eight out of 136 Ph-negative CML patients (including the cases in which 
CML diagnosis could not be verified [31]) showed evidence of BCR rearrangement, 
bcr-abl mRNA expression, or the presence of a 210 kD bcr-abl protein. 
2) Southern blot analysis detected a BCR breakpoint in 9 out of 10 Ph-negative 
CML patients with cytogenetic abnormalities involving chromosome 9 band q34, 
indicative for variant Ph translocation. Only one patient showed involvement of 
chromosome 9 band q34 without BCR rearrangement, although clinical and hemato- 
logic data were in favor of CML diagnosis [37]. However, it should be noticed that 
molecular data are scarce in this article: No details are mentioned about number of 
restriction enzyme digestions or probes used. Therefore, it cannot be ruled out that 
this patient also has a BCR rearrangement that was not detected in this study. When 
really no BCR breakpoint can be found using Southern blot analysis, it is worthwhile 
to search for a breakpoint more 5' in the BCR gene, e.g., using PCR technique on cDNA 
or pulse field gel electrophoresis (PFGE) on DNA. This case is possibly comparable 
with Ph-positive, BCR-negative cases that are described by Seller[ et al. [38, 39] and 
had a breakpoint in the first intron of the BCR gene or with the Ph-positive BCR- 
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Table 4 Cytogenet ic  and  molecu la r  data  on  pat ients  w i th  abnormal  karyotype  
of leukemic  ce l l s  
No. of BCR bcr-abl P210 
cases Karyotype breakpoint mRNA bcr-abl Reference 
A. CML patients with translocat ions involving 9q34 (n = 10) 
1 t(9;12)(q34;q21) (~ + 
1 t(9;11)(q34;q13) + + 
1 t(8;9)(?;q34) + 
1 t(9;18)(q34;?) + 
1 t(9;12)(q34;q13) + 
1 t(9;11)(q34;q11) + 
1 t(8;9)(q22;q34) + 
1 t(2;9)(?;q34) + 
1 t(3;7)(q21;q32), I' 
t(4;9]{q21 ;q34),del(8)(q22) 
1 t(9;9)(p13;q34) + 
B. CML patients with translocat ions not involving 9q34 (n = 5) 
1 t(20;21)(q11;q22) + 
ld  N/t(5;6) + 
ld  t(3;5) 
ld  t(9;15)(q22;q22),t(11;20) 
t(11:22]{q23;q13),del 7q, 
del(13] 
ND 
ND 
Bartram et al. (1985) [43] 
Kurzrock et al. (1986) {44] 
Bartram et al. (1988) [32] 
Bartram et al. (1988) {32] 
Weinstein et al. (1988) [63] 
and Eisenberg et al. 
{1988) [64] 
Weinstein et al. (1988) 163] 
and Eisenberg et al. 
(1988) [64] 
Weinstein et al. (1988) [63] 
Wiedemann et al. (1988) 
[31] 
Wang el al. (1988) [37] 
Sessarego et al. (1989) [67] 
Weinstein et al. (1988) [63] 
Wiedemann et al. (1988) 
[31] 
Wiedemann et al. (1988) 
[31] 
Wiedemann et al. (1988) 
(31] 
Wiedemann et al. (1988) 
1311 
C. CML patients in BC with abnormal karyotype, 9q34 not involved (n = 3) 
1 46,XY/47,XY, + 8 
1 46,XY/46,XY,i(17q] 
1 46,XX,t(7p q+,13q+,13q ), ND + 
D. Atypical CML patients with abnormal karyotype (n 4) 
1 del(16)(q22) + ': 
1 7q-  
1 t{8;21) 
1 47,XY, + 8 
Bartram et al. (1986) [581 
Bartram et al. (1986) ]58] 
Andrews et al. (1987) [66] 
Ganesan et al. (1986) [42] 
and Dreazen et al. (1987) 
1411 
Ohyashik i  et al. (1988) [61] 
Wiedemann et al. (1988) 
[31] 
Cogswell et al. (1989) [55] 
Abbreviotion: ND. not done. 
~Results in situ hybridization studies: c-abl on 12q - ,  5'-bcr on 12q - ,  3'-bcr on 9q +, c-sis on 22. 
bNo detailed molecular data presented in this article. 
':Extra bands in one restriction enzyme digest only. 
aCML patient in which diagnosis could not be verified. 
? Localization of breakpoint not mentioned. 
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Table 5 Molecular  data on patients with no abnormal it ies of chromosome 22 in leukemic 
cells (karyotype not further specified) 
No. of cases BCR breakpoint bcr-abl mRNA P210 bcr-abl Reference 
A. CML patients (n = 64) 
6 + 
2 
4 
11 + 
12 
1" 
27 
1 + 
B. Atypical CML patients (n = 5) 
4 
1 
5/5+ 
Shepherd et al. (1987) [30] 
Shepherd eta[. (1987) [30] 
Eisenberg et al. (1988) [64] 
Kantarjian et al. (1988) [60] 
Kantarjian et al. (1988) I60] 
Wiedemann et al. (1988) [31] 
Bartram et al. (1988) [321 
LoCoco et al. (1989) [65] 
Shepherd et al. (1987) [30] 
Wiedemann et al. (1988) [31] 
"CML patient in which diagnosis could not be verified [311. 
negative CML patient descr ibed by Bartram et al. [40], which had a breakpoint in the 
bcr gene located 5' of the BCR region but 3' of the region descr ibed by Selleri et al. 
[38, 39] 
3) In 20 out of 25 cases of aCML, no BCR breakpoint was detected. The five 
except ions with a BCR breakpoint were all reported by the same research group [41, 
42]. It wou ld  be interesting to reexamine the differential count and other cl inical data 
to check if these patients real ly belong to the group of aCML or resemble more CML. 
To the best of our knowledge,  no CMMoL or juveni le CML cases are publ ished in 
which a BCR rearrangement was identif ied. In conclusion,  bcr-abl  rearrangement is 
strongly associated with the morphologic  features of CML, although few exceptions 
still exist. 
4) The percentage of Ph-negative CML patients with BCR rearrangement versus no 
BCR rearrangement varied between the different authors, e.g., Bartram et al. [32, 58] 
reported 3 out of 12 cases BCR-positive; Ganesan et al. [42] and Dreazen et al. 1411, 5 
out of 5; Fitzgerald and Morris [46, 59], 2 out of 2; WiedeInann et al. [31], 8 out of 8 
(5 out of 9 among the cases that were not morphologica l ly  reexamined);  Kantarjian et 
al. [60], 11 out of 23; and our group, 5 out of 12 [45, this report]. In our opinion,  there 
are two main reasons responsible for these differences. First, the different authors 
used cl inical,  hematologic and morphologic  criteria that are not exactly the same, 
result ing in differences in diagnosis. Second, some authors [41, 42] diagnosed BCR 
breakpoints on extra bands in only one out of several different restriction enzyme 
Table 6 Molecular  data on CMMoL patients 
BCR bcr abl P210 In situ 
No. of cases breakpoint mRNA bcr-abl hybridization Reference 
A. Normal karyotype (n = 3} 
2 
1 ND 
B. Ph negative, karyotype not further specified (n = 18} 
1 
17 
c-abl on 9q 
Morris et al. (1986} 146] 
Fitzgerald et al. {1987) [59] 
Shepherd et al. (1987) [30] 
Kantarjian et al. (1988) ]60] 
Abbreviation: ND. not done. 
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digests. In such cases, the occurrem:e ofa restriction enzyme polynlorphism is a inore 
likely cause f()r the aberrant fragment than the l)reseo(:e of a BCR breakpoint. In such 
cases, additional analysis, e.g., at the protein or RNA level, is required to prove 
t)cr abl rearrangement. 
5) Molecular data presented in Tables 3-5 indicate that several mechanisms can 
play a role in Ph-negative CML. A sunnnary follows. 
Bcr-abl recombination takes place in the same way as in Ph-positive, CML but is 
cytogenetically not visible. Examples ()f complex Ph translocations in Ph-negative 
CML are provided by Bartram et al. I43[, Kurzrock et al. [44] and our data [45]. In situ 
hybridization studies of Ph-negatiw ~, CML patients reported by Bartram el al. [43] and 
our own group [45] provided evidence that 5'-bcr and c-obl were localized on the 
same chromosomal segment. However, in these special cases, the hybrid bcr-abl gene 
was present on a third chromosome instead of on the Ph chromosome. In these cases, 
the localization of the hybrid bcr-abl gene indicated that complex Ph translocations 
had occurred, although the aspect of chromosome 22 was visibly unaltered. 
Insertion of part of the abl gene in the bcr gene without reciprocal translocation to
chromosome 9 has been described by Morris et al. [46] and Dreazen et al. [41]. 
Based on investigations in a Ph-negatiw,' CML patient in which BCR was rearrange(l 
without juxtaposition of (:-(dJl, Bartram [47] prot)()sed the hypothesis that bcr or abl 
can work in combination with vet another oncogene. Thus far. there is no further 
evideo(:e for this hypothesis. 
Seve, ra[ other possibilities remain open h)r dis(:ussiou in Ph-negative, BCR-m~gative 
cases indistinguishable from I'll-positive (]ML (m clinical anti hematoh)gi(: as well as 
morphologic criteria. Three hypothetic me(:hanisms (:ouht ext)lain these t)henomena: 
1) The t)reakpoint might I)e h)(:ate(t outsi(te the BCR, but within the B(]R gene as 
described by Se]leri e,t al. [38, 39] and Bartram eta]. [401 in Ph-positive CML cases. 
Both authors reported breakpoint localizati()ns more 5' in the BCtl gene. 
2) Abl possibly cooperates with an as yet unknown oncogene. 
3) Neither bcr nor abl are responsible for the disease in exceptional cases, but other 
oncogenes might be. Thus far, the few data available on this subject do not identify 
candidate genes for this latter hypothesis [48 54]. Recently, Cogswell et al. [55] 
reported that using the polymerase chain reaction very few ras mutations were detect- 
able in CML, i.e., in 1 out ()f 18 Ph-positive CML patients in blast crisis and in 0 out 
of 39 Ph-positive (]NIL cases in chronic phase. However, in Ph-negative, BCR-negative 
atypical Cl'vlL {aCML), they [55I delnonstrate(t the presence of ras mutations in 54% 
(i.e.. 7/13) of the cases. This high fre, quen(:y of r(Is mutations is (:omparable with 
results obtained 133, Padua et al. [561 in CMMoL patients. CMMoL and aCML also share 
several clinical and hematoh)gi(: features. The authors therefore conclude that aCML 
is a subgroup of CMMol, and that both diseases belong to MDS rather than CM[,. 
CONCLUSION 
Correct diagnosis of CML is essential when efforts are made to (:orrelate clinical 
features with molecular changes in Ph-negative CML. The data reviewed in this article 
do not identify any clinical or hematologic (:haracteristi(: that is unique for Ph-negative 
CML. We expected that in nearly all Ph-negative CML patients, indistinguishable 
from Ph-positive CML on (:lini(:al and hematologic grounds, t)cr-abl rearrangement 
will be detected using molecular analysis. The data on Ph-negative CML reviewed in 
this article show the presence of bcr abl rearrangement in 43% of the cases (Table 
7). Although no evidence was found for bcr-abl rearrangement i  he remaining 57%, 
in many cases no definitive proof was provided to rule out this possibility. On the 
other hand, it can not be den ied  that several CML patients are reported with classical 
CML disease without he presence of bcr-abl rearrangement. Very recently, this was 
confirmed by Kurzrock et al. [571, who reported on 11 Ph-negative, BCR-negative CML 
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Table 7 Distribution of Pb-negative CML patients in chronic phase 
or blast crisis according to results of cytogenetic and 
molecular studies 
No. of cases 
Molecular 
evideilce 
for BCR 
tea rra ngemenl 
Karyotype Yes No 
54 
10 
8 
64 
Normal 28 26 
Abnormal, 9q34 involved 9 1 
Abnormal, q34 not involved 3 5 
Ph-negative, karyotype not specified 18 46 
cases investigated in the MD Anderson Cancer Center using Southern and Northern 
blot analysis. They represented about 3% of the CML cases studied in the same period 
in that institute. In addition to our findings, Kurzrock et al. reported that, although 
the early stage of BCR-negative and BCR-positive CML shows striking resemblam:e, 
disease progression manifests distinctly. 
In the Ph-negative patients (tile aCML patients) that do not fulfill all criteria for 
CML, a more heterogeneous picture can be expected, showing activation of other 
oncogenes than bcr and abl e.g., ras, in some cases. 
A controlled multicenter study of Ph-negative CML patients who are clinically, 
hematologically, and cytogenetically well characterized should form the basis for 
future molecular investigations necessary to elucidate the mechanisms responsible 
for Ph negative CML and to apply this knowledge to determine choice of therapy and 
prognosis. 
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